NEWS
Bloodstream Infections - From Threats to Solutions
Investorideas.com published the second part of a series on blood infections treatment, featuring Citius Pharmaceuticals (NASDAQ: CTXR). Citius has made significant advances in its late-stage product candidates, particularly Mino-Lok® for catheter-related bloodstream infections (CRBSIs). The Phase 3 trial of Mino-Lok® showed positive topline results, meeting primary and secondary endpoints with statistical significance. The primary endpoint was the time to catheter failure, with Mino-Lok achieving superior results compared to the control arm. The next steps include FDA submission and a Type B meeting. Mino-Lok® could potentially set a new standard of care by offering a non-invasive alternative to catheter removal and replacement. The Phase 3 trial data indicates that Mino-Lok® is well-tolerated and effective, demonstrating a substantial delay in catheter failure events compared to the control group. In addition, BD is addressing supply issues for blood culture vials, and CorMedix has launched DefenCath® for outpatient dialysis centers. Vir Biotechnology received FDA clearance for its hepatitis delta treatment combination, highlighting the ongoing innovations in the infection treatment market.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1170Followers
73Following
8192Visitors
Follow